Lyell Immunopharma (LYEL) Prepaid Assets (2020 - 2026)
Lyell Immunopharma recorded quarterly Prepaid Assets of $13.3 million in Q1 2026, down 3.19% quarter-over-quarter from $13.7 million in Q4 2025, and up 65.99% year-over-year from $8.0 million in Q1 2025.
Lyell Immunopharma's Prepaid Assets history runs 7 years deep, the most recent figure standing at $13.3 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 65.99% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 65.99% YoY), while the FY2025 annual figure was $13.7 million, up 51.31% from the prior year.
- Prepaid Assets came in at $13.3 million for Q1 2026 at Lyell Immunopharma, down from $13.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $13.7 million in Q4 2025 to a low of $5.4 million in Q2 2025.
- A 5-year average of $10.1 million and a median of $10.7 million in 2023 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets sank 37.69% in 2025 and soared 65.99% in 2026, its largest moves.
- Lyell Immunopharma's Prepaid Assets stood at $11.1 million in 2022, then fell by 24.05% to $8.5 million in 2023, then increased by 7.14% to $9.1 million in 2024, then jumped by 51.31% to $13.7 million in 2025, then declined by 3.19% to $13.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $13.3 million, $13.7 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.28 Mn |
| Dec 31, 2025 | 13.72 Mn |
| Sep 30, 2025 | 8.58 Mn |
| Jun 30, 2025 | 5.42 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 9.07 Mn |
| Sep 30, 2024 | 9.50 Mn |
| Jun 30, 2024 | 8.71 Mn |
| Mar 31, 2024 | 7.87 Mn |
| Dec 31, 2023 | 8.46 Mn |
| Sep 30, 2023 | 11.42 Mn |
| Jun 30, 2023 | 10.66 Mn |
| Mar 31, 2023 | 11.63 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | 11.61 Mn |
| Jun 30, 2022 | 11.21 Mn |
| Mar 31, 2022 | 11.79 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Sep 30, 2021 | 12.23 Mn |
| Jun 30, 2021 | 10.32 Mn |
| Dec 31, 2020 | 4.93 Mn |